Breast Cancer Clinical Trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Summary

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

View Full Description

Full Description

PRIMARY OBJECTIVE:

I. To compare breast cancer event-free survival between participants randomized to standard of care neoadjuvant chemotherapy alone versus standard of care neoadjuvant chemotherapy concurrent with durvalumab.

SECONDARY OBJECTIVES:

I. To compare pathologic complete response rates (ypT0/is, ypN0) in participants randomized to standard of care chemotherapy alone versus (vs.) standard of care neoadjuvant chemotherapy concurrent with durvalumab.

II. To compare residual cancer burden distribution between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab.

III. To compare distant relapse-free survival between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab.

IV. To compare overall survival between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab.

V. To compare the frequency and severity of toxicities between participants randomized to standard of care neoadjuvant chemotherapy vs. standard of care neoadjuvant chemotherapy concurrent with durvalumab among those who initiate the assigned treatment.

PRIMARY QUALITY OF LIFE (QOL) OBJECTIVES:

I. To compare the change in fatigue (Patient Reported Outcomes Measurement Information System [PROMIS] Fatigue) experienced by participants randomized to neoadjuvant durvalumab plus chemotherapy vs. participants randomized to chemotherapy alone at completion of active treatment (at 20 weeks from baseline).

II. To compare the change in global physical health (PROMIS Global Health) experienced by participants randomized to neoadjuvant durvalumab plus chemotherapy vs participants randomized to chemotherapy alone at completion of active treatment (at 20 weeks from baseline).

SECONDARY QOL OBJECTIVES:

I. To compare the change in fatigue and global physical health experienced by participants randomized to neoadjuvant durvalumab plus chemotherapy vs participants randomized to chemotherapy alone during treatment (at 12 weeks from baseline).

II. To compare the changes in global physical health and fatigue subsequent to treatment (at years 1 and 2) between the two randomized study arms.

III. To compare the severity and frequency of treatment-related symptoms using Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) items (diarrhea, nausea, cough, shortness of breath, rash, and musculoskeletal pain) over time experienced by patients receiving neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone.

BANKING OBJECTIVE:

I. To bank specimens for future correlative studies.

OUTLINE:

STEP 1: Patients without a known MammaPrint Ultrahigh (MP2) score undergo MammaPrint testing on a previously-collected tissue sample. Patients with MP2 score proceed to STEP 2.

STEP 2: Patients are randomized to 1 of 2 arms.

ARM 1: Patients receive paclitaxel intravenously (IV) over 30-60 minutes on days 1 and 8 of each cycle. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV over 30 minutes on day 1 of each cycle. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.

ARM 2: Patients receive paclitaxel IV over 30-60 minutes on days 1 and 8 of every cycle and durvalumab IV over 60 minutes on day 1 of every other cycle. Treatment repeats every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive doxorubicin IV and cyclophosphamide IV over 30 minutes on day 1 of each cycle, and durvalumab IV over 60 minutes on day 1 of every other cycle. Treatment repeats every 14 days for 4 cycles in the absence of disease progression or unacceptable toxicity.

All patients also undergo mammography during screening (STEP 1). Patients have the option to also undergo collection of tumor tissue during initial biopsy (STEP 1) and at standard of care (SOC) surgery, and undergo collection of blood samples prior to STEP 2 treatment, after cycle one of chemotherapy, and one month post-SOC surgery.

After completion of study treatment, patients are followed until death or 10 years, whichever occurs first.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

STEP 1: REGISTRATION (SCREENING): Participants must have histologically confirmed estrogen receptor (ER) positive and/or progesterone receptor (PR) positive (hormone receptor positive) and HER2 negative breast cancer, as per American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines

NOTE: Participants with HER2 positive disease by ASCO CAP guidelines are ineligible. HER2 negative and HER2 low or equivocal cases as per ASCO CAP guidelines that do not receive HER2 targeted therapy are eligible

STEP 1: REGISTRATION (SCREENING): Participants must have clinical stage II or III breast cancer

NOTE: Participants with inflammatory breast cancer are eligible
STEP 1: REGISTRATION (SCREENING): Participants must not have metastatic disease (i.e., must be clinically M0 or Mx) Systemic staging studies with imaging should follow routine practice as per National Comprehensive Cancer Network (NCCN) and ASCO guidelines
STEP 1: REGISTRATION (SCREENING): Participants must not have locally recurrent breast cancer
STEP 1: REGISTRATION (SCREENING): Participants with multifocal disease or synchronous primary tumors are eligible, however, all tumors must be hormone receptor positive and HER2 negative per ASCO CAP guidelines. It is sufficient to have MP2 status on at least one of the lesions

Participants must have either adequate tissue available to submit on-study or a prior known MammaPrint Index Score that is MP2 status

Submitting tissue for on-study MammaPrint testing:

Participants must have a minimum of ten, unstained formalin-fixed paraffin-embedded (FFPE) slides (4-5 micron thickness) available from initial tumor biopsy for MammaPrint assessment

NOTE: Participants must agree to have this tissue submitted to Agendia for MammaPrint Index Scoring and to have subsequent results disclosed to SWOG Cancer Research Network OR

Submitting prior known MammaPrint Index Score:

If a MammaPrint Index Score report from within the last 12 weeks is already known and is MP2 status, the participant must be registered to Step 2 immediately following Step 1 registration provided they meet all other criteria. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 0.57) tested from initial tumor biopsy

NOTE: Participants must agree to have their commercial MammaPrint Index Score disclosed to Southwest Oncology Group (SWOG) Cancer Research Network
NOTE: Participants with prior known MammaPrint result that is not MP2 status should not be enrolled to either step of this study
STEP 1: REGISTRATION (SCREENING): Participants must not have received any prior treatment for their current breast cancer, including chemotherapy, immunotherapy, biologic or hormonal therapy, and must be candidates for doxorubicin, paclitaxel, and durvalumab therapy
STEP 1: REGISTRATION (SCREENING): Participants must be >= 18 years old at the time of registration
STEP 1: REGISTRATION (SCREENING): Participants must have a complete medical history and physical exam within 28 days prior to Step 1 Registration
STEP 1: REGISTRATION (SCREENING): Participants must have body weight > 30 kg
STEP 1: REGISTRATION (SCREENING): Participants must have Zubrod Performance Status of 0-2
STEP 1: REGISTRATION (SCREENING): Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
STEP 1: REGISTRATION (SCREENING): Participant must not have medical contraindications to receiving immunotherapy, including history of non-infectious pneumonitis that required steroids or active autoimmune disease that has required systemic treatment with disease modifying agents, corticosteroids or immunosuppressive drugs in the past two years. Replacement therapy (e.g. thyroxine for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Intra-articular steroid injections are allowed

STEP 1: REGISTRATION (SCREENING): NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system

Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
STEP 2: RANDOMIZATION: Participants must have met all eligibility criteria for Step 1 Registration

STEP 2: RANDOMIZATION: Participants must have MP2 MammaPrint result

For participants submitting tissue for on-study MammaPrint testing:

Participants must be registered to Step 2: Randomization within 84 calendar days (12 weeks) after receiving an MP2 status from the MammaPrint Index score. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 0.57) from initial tumor biopsy OR

Submitting commercial MammaPrint Index Score:

If a MammaPrint Index Score report from within the last 12 weeks is already known and is MP2 status, the participant must be registered to Step 2 immediately following Step 1 registration provided they meet all other criteria. MP2 status is defined as a MammaPrint Index score between negative 1.0 and negative 0.57 (-1.0 to -0.57, including negative 0.57) tested from initial tumor biopsy
STEP 2: RANDOMIZATION: Participants must not have received live vaccines within 28 days prior to study Step 2: Randomization. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines and coronavirus disease 2019 (COVID-19) vaccines are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist) are live attenuated vaccines, and are not allowed
STEP 2: RANDOMIZATION: Participants must not be planning to receive any concurrent non-protocol directed chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study
STEP 2: RANDOMIZATION: Participant must have Zubrod Performance Status of 0-2
STEP 2: RANDOMIZATION: Participants must not have a history of (non-infectious) pneumonitis that required steroids or evidence of active pneumonitis within two years prior to Step 2: Randomization
STEP 2: RANDOMIZATION: Participants must not have active autoimmune disease that has required systemic treatment in the past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) prior to Step 2: Randomization. Replacement therapy (e.g. thyroxine for pre-existing hypothyroidism, insulin for type I diabetes mellitus, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Intra-articular steroid injections are allowed
STEP 2: RANDOMIZATION: Participant must have a complete medical history and physical exam within 28 days prior to Step 2: Randomization
STEP 2: RANDOMIZATION: Leukocytes >= 3 x 10^3/uL (within 28 days prior to Step 2: Randomization)
STEP 2: RANDOMIZATION: Absolute neutrophil count >=1.5 x 10^3/uL (within 28 days prior to Step 2: Randomization)
STEP 2: RANDOMIZATION: Platelets >= 100 x 10^3/uL (within 28 days prior to Step 2: Randomization)
STEP 2: RANDOMIZATION: Total bilirubin =< institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =< 5 x institutional ULN (within 28 days prior to Step 2: Randomization)
STEP 2: RANDOMIZATION: AST/ALT =< 3 × institutional ULN (within 28 days prior to Step 2: Randomization)
STEP 2: RANDOMIZATION: Participants must have a calculated creatinine clearance >= 50 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to Step 2: Randomization
STEP 2: RANDOMIZATION: Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better
STEP 2: RANDOMIZATION: Participants must not have uncontrolled diabetes defined as hemoglobin A1c of 9.0% or greater, within 28 days prior to Step 2: Randomization.
STEP 2: RANDOMIZATION: Participants with history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have an undetectable viral load on the most recent test results obtained within 6 months prior to Step 2: Randomization
STEP 2: RANDOMIZATION: Participants with history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load on the most recent test results obtained while on suppressive therapy within 6 months prior to Step 2: Randomization, if indicated
STEP 2: RANDOMIZATION: Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load on the most recent test results obtained within 6 months prior to Step 2: Randomization, if indicated
STEP 2: RANDOMIZATION: Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during protocol therapy and for 6 months following completion of protocol therapy with details provided as a part of the consent process and must have a negative pregnancy test at screening. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen. Participants should not breastfeed during protocol therapy and for 6 months following completion of protocol therapy.
STEP 2: RANDOMIZATION: Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the SWOG Specimen Tracking System
STEP 2: RANDOMIZATION: Participants who can complete questionnaires in English, or Spanish must be offered the opportunity to participate in the Quality of Life study
STEP 2: RANDOMIZATION: NOTE: As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
STEP 2: RANDOMIZATION: Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

Study is for people with:

Breast Cancer

Phase:

Phase 3

Estimated Enrollment:

3680

Study ID:

NCT06058377

Recruitment Status:

Recruiting

Sponsor:

National Cancer Institute (NCI)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 179 Locations for this study

See Locations Near You

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro Arkansas, 72401, United States More Info
Site Public Contact
Contact
870-936-7066
[email protected]
Ryan A. Yates
Principal Investigator
Sutter Auburn Faith Hospital
Auburn California, 95602, United States More Info
Site Public Contact
Contact
[email protected]
Kristie A. Bobolis
Principal Investigator
AIS Cancer Center at San Joaquin Community Hospital
Bakersfield California, 93301, United States More Info
Site Public Contact
Contact
661-323-4673
Nicole Gordon
Principal Investigator
Alta Bates Summit Medical Center-Herrick Campus
Berkeley California, 94704, United States More Info
Site Public Contact
Contact
[email protected]
Kristie A. Bobolis
Principal Investigator
Tower Cancer Research Foundation
Beverly Hills California, 90211, United States More Info
Site Public Contact
Contact
[email protected]
Jin Sun L. Bitar
Principal Investigator
City of Hope Comprehensive Cancer Center
Duarte California, 91010, United States More Info
Site Public Contact
Contact
800-826-4673
[email protected]
Danny Nguyen
Principal Investigator
Palo Alto Medical Foundation-Fremont
Fremont California, 94538, United States More Info
Site Public Contact
Contact
[email protected]
Kristie A. Bobolis
Principal Investigator
City of Hope at Irvine Lennar
Irvine California, 92618, United States More Info
Site Public Contact
Contact
877-467-3411
Danny Nguyen
Principal Investigator
Cedars Sinai Medical Center
Los Angeles California, 90048, United States More Info
Site Public Contact
Contact
310-423-8965
Jin Sun L. Bitar
Principal Investigator
Memorial Medical Center
Modesto California, 95355, United States More Info
Site Public Contact
Contact
[email protected]
Kristie A. Bobolis
Principal Investigator
City of Hope Newport Beach
Newport Beach California, 92660, United States More Info
Site Public Contact
Contact
877-467-3411
Danny Nguyen
Principal Investigator
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange California, 92868, United States More Info
Site Public Contact
Contact
877-827-8839
[email protected]
Ritesh Parajuli
Principal Investigator
Desert Regional Medical Center
Palm Springs California, 92262, United States More Info
Site Public Contact
Contact
760-416-4730
Scott Brook
Principal Investigator
Palo Alto Medical Foundation Health Care
Palo Alto California, 94301, United States More Info
Site Public Contact
Contact
[email protected]
Kristie A. Bobolis
Principal Investigator
Sutter Roseville Medical Center
Roseville California, 95661, United States More Info
Site Public Contact
Contact
[email protected]
Kristie A. Bobolis
Principal Investigator
Sutter Medical Center Sacramento
Sacramento California, 95816, United States More Info
Site Public Contact
Contact
[email protected]
Kristie A. Bobolis
Principal Investigator
California Pacific Medical Center-Pacific Campus
San Francisco California, 94115, United States More Info
Site Public Contact
Contact
[email protected]
Kristie A. Bobolis
Principal Investigator
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz California, 95065, United States More Info
Site Public Contact
Contact
[email protected]
Kristie A. Bobolis
Principal Investigator
City of Hope South Pasadena
South Pasadena California, 91030, United States More Info
Site Public Contact
Contact
800-826-4673
[email protected]
Danny Nguyen
Principal Investigator
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale California, 94086, United States More Info
Site Public Contact
Contact
[email protected]
Kristie A. Bobolis
Principal Investigator
City of Hope Upland
Upland California, 91786, United States More Info
Site Public Contact
Contact
800-826-4673
[email protected]
Danny Nguyen
Principal Investigator
Sutter Solano Medical Center/Cancer Center
Vallejo California, 94589, United States More Info
Site Public Contact
Contact
[email protected]
Kristie A. Bobolis
Principal Investigator
Shaw Cancer Center
Edwards Colorado, 81632, United States More Info
Site Public Contact
Contact
970-569-7429
Alexander T. Urquhart
Principal Investigator
Smilow Cancer Hospital-Derby Care Center
Derby Connecticut, 06418, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Smilow Cancer Hospital Care Center-Fairfield
Fairfield Connecticut, 06824, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Smilow Cancer Hospital Care Center at Glastonbury
Glastonbury Connecticut, 06033, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Smilow Cancer Hospital Care Center at Greenwich
Greenwich Connecticut, 06830, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Smilow Cancer Hospital Care Center - Guilford
Guilford Connecticut, 06437, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Smilow Cancer Hospital Care Center at Saint Francis
Hartford Connecticut, 06105, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Yale University
New Haven Connecticut, 06520, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Yale-New Haven Hospital North Haven Medical Center
North Haven Connecticut, 06473, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Smilow Cancer Hospital Care Center at Long Ridge
Stamford Connecticut, 06902, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Smilow Cancer Hospital-Torrington Care Center
Torrington Connecticut, 06790, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Smilow Cancer Hospital Care Center-Trumbull
Trumbull Connecticut, 06611, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Smilow Cancer Hospital-Waterbury Care Center
Waterbury Connecticut, 06708, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Smilow Cancer Hospital Care Center - Waterford
Waterford Connecticut, 06385, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Helen F Graham Cancer Center
Newark Delaware, 19713, United States More Info
Site Public Contact
Contact
302-623-4450
[email protected]
Gregory A. Masters
Principal Investigator
Medical Oncology Hematology Consultants PA
Newark Delaware, 19713, United States More Info
Site Public Contact
Contact
302-623-4450
[email protected]
Gregory A. Masters
Principal Investigator
Jupiter Medical Center
Jupiter Florida, 33458, United States More Info
Site Public Contact
Contact
561-745-5768
Debra S. Brandt
Principal Investigator
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah Georgia, 31405, United States More Info
Site Public Contact
Contact
912-819-5704
[email protected]
Catherine A. Ronaghan
Principal Investigator
Saint Alphonsus Cancer Care Center-Boise
Boise Idaho, 83706, United States More Info
Site Public Contact
Contact
734-712-3671
[email protected]
John M. Schallenkamp
Principal Investigator
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell Idaho, 83605, United States More Info
Site Public Contact
Contact
734-712-3671
[email protected]
John M. Schallenkamp
Principal Investigator
Kootenai Health - Coeur d'Alene
Coeur d'Alene Idaho, 83814, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Saint Alphonsus Cancer Care Center-Nampa
Nampa Idaho, 83687, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Kootenai Clinic Cancer Services - Post Falls
Post Falls Idaho, 83854, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Kootenai Cancer Clinic
Sandpoint Idaho, 83864, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Illinois CancerCare-Bloomington
Bloomington Illinois, 61704, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Canton
Canton Illinois, 61520, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Carthage
Carthage Illinois, 62321, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Carle at The Riverfront
Danville Illinois, 61832, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Pratima Chalasani
Principal Investigator
Cancer Care Specialists of Illinois - Decatur
Decatur Illinois, 62526, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Decatur Memorial Hospital
Decatur Illinois, 62526, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Dixon
Dixon Illinois, 61021, United States More Info
Site Public Contact
Contact
815-285-7800
Bryan A. Faller
Principal Investigator
Carle Physician Group-Effingham
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Pratima Chalasani
Principal Investigator
Crossroads Cancer Center
Effingham Illinois, 62401, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Eureka
Eureka Illinois, 61530, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Galesburg
Galesburg Illinois, 61401, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Kewanee Clinic
Kewanee Illinois, 61443, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Macomb
Macomb Illinois, 61455, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Carle Physician Group-Mattoon/Charleston
Mattoon Illinois, 61938, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Pratima Chalasani
Principal Investigator
Trinity Medical Center
Moline Illinois, 61265, United States More Info
Site Public Contact
Contact
309-779-2000
Pratima Chalasani
Principal Investigator
Cancer Care Center of O'Fallon
O'Fallon Illinois, 62269, United States More Info
Site Public Contact
Contact
217-876-4762
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Ottawa Clinic
Ottawa Illinois, 61350, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Pekin
Pekin Illinois, 61554, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Peoria
Peoria Illinois, 61615, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Peru
Peru Illinois, 61354, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Illinois CancerCare-Princeton
Princeton Illinois, 61356, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Memorial Hospital East
Shiloh Illinois, 62269, United States More Info
Site Public Contact
Contact
314-747-9912
[email protected]
Lindsay L. Peterson
Principal Investigator
Southern Illinois University School of Medicine
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
217-545-7929
Bryan A. Faller
Principal Investigator
Springfield Clinic
Springfield Illinois, 62702, United States More Info
Site Public Contact
Contact
800-444-7541
Bryan A. Faller
Principal Investigator
Memorial Medical Center
Springfield Illinois, 62781, United States More Info
Site Public Contact
Contact
217-528-7541
[email protected]
Bryan A. Faller
Principal Investigator
Carle Cancer Center
Urbana Illinois, 61801, United States More Info
Site Public Contact
Contact
800-446-5532
[email protected]
Pratima Chalasani
Principal Investigator
Illinois CancerCare - Washington
Washington Illinois, 61571, United States More Info
Site Public Contact
Contact
309-243-3605
[email protected]
Bryan A. Faller
Principal Investigator
Northwest Cancer Center - Main Campus
Crown Point Indiana, 46307, United States More Info
Site Public Contact
Contact
219-310-2550
Pratima Chalasani
Principal Investigator
Northwest Oncology LLC
Dyer Indiana, 46311, United States More Info
Site Public Contact
Contact
219-924-8178
Pratima Chalasani
Principal Investigator
Northwest Cancer Center - Hobart
Hobart Indiana, 46342, United States More Info
Site Public Contact
Contact
219-947-1795
Pratima Chalasani
Principal Investigator
Saint Mary Medical Center
Hobart Indiana, 46342, United States More Info
Site Public Contact
Contact
219-836-6875
[email protected]
Pratima Chalasani
Principal Investigator
Saint Catherine Hospital
Indianapolis Indiana, 46312, United States More Info
Site Public Contact
Contact
[email protected]
Pratima Chalasani
Principal Investigator
The Community Hospital
Munster Indiana, 46321, United States More Info
Site Public Contact
Contact
219-836-3349
Pratima Chalasani
Principal Investigator
Women's Diagnostic Center - Munster
Munster Indiana, 46321, United States More Info
Site Public Contact
Contact
219-934-8869
[email protected]
Pratima Chalasani
Principal Investigator
Northwest Cancer Center - Valparaiso
Valparaiso Indiana, 46383, United States More Info
Site Public Contact
Contact
219-836-6875
[email protected]
Pratima Chalasani
Principal Investigator
Mission Cancer and Blood - Ankeny
Ankeny Iowa, 50023, United States More Info
Site Public Contact
Contact
515-282-2921
Richard L. Deming
Principal Investigator
Medical Oncology and Hematology Associates-West Des Moines
Clive Iowa, 50325, United States More Info
Site Public Contact
Contact
515-241-3305
Richard L. Deming
Principal Investigator
Mercy Medical Center - Des Moines
Des Moines Iowa, 50314, United States More Info
Site Public Contact
Contact
515-358-6613
[email protected]
Richard L. Deming
Principal Investigator
Mission Cancer and Blood - Laurel
Des Moines Iowa, 50314, United States More Info
Site Public Contact
Contact
515-241-3305
Richard L. Deming
Principal Investigator
University of Kansas Cancer Center
Kansas City Kansas, 66160, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Priyanka Sharma
Principal Investigator
University of Kansas Cancer Center-Overland Park
Overland Park Kansas, 66210, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Priyanka Sharma
Principal Investigator
University of Kansas Hospital-Indian Creek Campus
Overland Park Kansas, 66211, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Priyanka Sharma
Principal Investigator
University of Kansas Hospital-Westwood Cancer Center
Westwood Kansas, 66205, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Priyanka Sharma
Principal Investigator
Sinai Hospital of Baltimore
Baltimore Maryland, 21215, United States More Info
Site Public Contact
Contact
410-601-6120
[email protected]
Maitri Kalra
Principal Investigator
William E Kahlert Regional Cancer Center/Sinai Hospital
Westminster Maryland, 21157, United States More Info
Site Public Contact
Contact
410-871-6400
Maitri Kalra
Principal Investigator
Saint Joseph Mercy Hospital
Ann Arbor Michigan, 48106, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
University of Michigan Comprehensive Cancer Center
Ann Arbor Michigan, 48109, United States More Info
Site Public Contact
Contact
800-865-1125
Erin F. Cobain
Principal Investigator
Saint Joseph Mercy Brighton
Brighton Michigan, 48114, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton Michigan, 48114, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Saint Joseph Mercy Canton
Canton Michigan, 48188, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton Michigan, 48188, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Caro Cancer Center
Caro Michigan, 48723, United States More Info
Site Public Contact
Contact
989-907-8411
[email protected]
Elie G. Dib
Principal Investigator
Saint Joseph Mercy Chelsea
Chelsea Michigan, 48118, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea Michigan, 48118, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Genesee Cancer and Blood Disease Treatment Center
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Elie G. Dib
Principal Investigator
Genesee Hematology Oncology PC
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Elie G. Dib
Principal Investigator
Genesys Hurley Cancer Institute
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Elie G. Dib
Principal Investigator
Hurley Medical Center
Flint Michigan, 48503, United States More Info
Site Public Contact
Contact
810-762-8038
[email protected]
Elie G. Dib
Principal Investigator
University of Michigan Health - Sparrow Lansing
Lansing Michigan, 48912, United States More Info
Site Public Contact
Contact
517-364-3712
[email protected]
Elie G. Dib
Principal Investigator
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia Michigan, 48154, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Ascension Providence Hospitals - Novi
Novi Michigan, 48374, United States More Info
Site Public Contact
Contact
248-849-5332
[email protected]
Adam M. Forman
Principal Investigator
Saint Joseph Mercy Oakland
Pontiac Michigan, 48341, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Ascension Saint Mary's Hospital
Saginaw Michigan, 48601, United States More Info
Site Public Contact
Contact
989-907-8411
[email protected]
Elie G. Dib
Principal Investigator
Oncology Hematology Associates of Saginaw Valley PC
Saginaw Michigan, 48604, United States More Info
Site Public Contact
Contact
989-907-8411
[email protected]
Elie G. Dib
Principal Investigator
Ascension Providence Hospitals - Southfield
Southfield Michigan, 48075, United States More Info
Site Public Contact
Contact
248-849-5332
[email protected]
Adam M. Forman
Principal Investigator
Ascension Saint Joseph Hospital
Tawas City Michigan, 48764, United States More Info
Site Public Contact
Contact
989-907-8411
[email protected]
Elie G. Dib
Principal Investigator
Saint Mary's Oncology/Hematology Associates of West Branch
West Branch Michigan, 48661, United States More Info
Site Public Contact
Contact
989-907-8411
[email protected]
Elie G. Dib
Principal Investigator
Huron Gastroenterology PC
Ypsilanti Michigan, 48106, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti Michigan, 48197, United States More Info
Site Public Contact
Contact
734-712-7251
[email protected]
Elie G. Dib
Principal Investigator
Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus Mississippi, 39705, United States More Info
Site Public Contact
Contact
901-226-1366
[email protected]
Ryan A. Yates
Principal Investigator
Baptist Cancer Center-Grenada
Grenada Mississippi, 38901, United States More Info
Site Public Contact
Contact
901-226-1366
[email protected]
Ryan A. Yates
Principal Investigator
Baptist Memorial Hospital and Cancer Center-Union County
New Albany Mississippi, 38652, United States More Info
Site Public Contact
Contact
901-226-1366
[email protected]
Ryan A. Yates
Principal Investigator
Baptist Memorial Hospital and Cancer Center-Oxford
Oxford Mississippi, 38655, United States More Info
Site Public Contact
Contact
901-226-1366
[email protected]
Ryan A. Yates
Principal Investigator
Baptist Memorial Hospital and Cancer Center-Desoto
Southhaven Mississippi, 38671, United States More Info
Site Public Contact
Contact
901-226-1366
[email protected]
Ryan A. Yates
Principal Investigator
Saint Francis Medical Center
Cape Girardeau Missouri, 63703, United States More Info
Site Public Contact
Contact
573-334-2230
[email protected]
Bryan A. Faller
Principal Investigator
Siteman Cancer Center at West County Hospital
Creve Coeur Missouri, 63141, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Lindsay L. Peterson
Principal Investigator
Parkland Health Center - Farmington
Farmington Missouri, 63640, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
University of Kansas Cancer Center - North
Kansas City Missouri, 64154, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Priyanka Sharma
Principal Investigator
University of Kansas Cancer Center - Lee's Summit
Lee's Summit Missouri, 64064, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Priyanka Sharma
Principal Investigator
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City Missouri, 64116, United States More Info
Site Public Contact
Contact
913-588-3671
[email protected]
Priyanka Sharma
Principal Investigator
Washington University School of Medicine
Saint Louis Missouri, 63110, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Lindsay L. Peterson
Principal Investigator
Siteman Cancer Center-South County
Saint Louis Missouri, 63129, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Lindsay L. Peterson
Principal Investigator
Missouri Baptist Medical Center
Saint Louis Missouri, 63131, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Siteman Cancer Center at Christian Hospital
Saint Louis Missouri, 63136, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Lindsay L. Peterson
Principal Investigator
Siteman Cancer Center at Saint Peters Hospital
Saint Peters Missouri, 63376, United States More Info
Site Public Contact
Contact
800-600-3606
[email protected]
Lindsay L. Peterson
Principal Investigator
Sainte Genevieve County Memorial Hospital
Sainte Genevieve Missouri, 63670, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Missouri Baptist Sullivan Hospital
Sullivan Missouri, 63080, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
BJC Outpatient Center at Sunset Hills
Sunset Hills Missouri, 63127, United States More Info
Site Public Contact
Contact
314-996-5569
Bryan A. Faller
Principal Investigator
Community Hospital of Anaconda
Anaconda Montana, 59711, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Billings Clinic Cancer Center
Billings Montana, 59101, United States More Info
Site Public Contact
Contact
800-996-2663
[email protected]
John M. Schallenkamp
Principal Investigator
Bozeman Deaconess Hospital
Bozeman Montana, 59715, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Benefis Healthcare- Sletten Cancer Institute
Great Falls Montana, 59405, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Community Medical Hospital
Missoula Montana, 59804, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
OptumCare Cancer Care at Seven Hills
Henderson Nevada, 89052, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
John A. Ellerton
Principal Investigator
OptumCare Cancer Care at Charleston
Las Vegas Nevada, 89102, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
John A. Ellerton
Principal Investigator
OptumCare Cancer Care at Fort Apache
Las Vegas Nevada, 89148, United States More Info
Site Public Contact
Contact
702-384-0013
[email protected]
John A. Ellerton
Principal Investigator
Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus
Elizabeth New Jersey, 07207, United States More Info
Site Public Contact
Contact
908-994-8000
Mridula A. George
Principal Investigator
The Cancer Institute of New Jersey Hamilton
Hamilton New Jersey, 08690, United States More Info
Site Public Contact
Contact
609-631-6946
Mridula A. George
Principal Investigator
Jersey City Medical Center
Jersey City New Jersey, 07302, United States More Info
Site Public Contact
Contact
888-823-5923
[email protected]
Mridula A. George
Principal Investigator
Monmouth Medical Center Southern Campus
Lakewood New Jersey, 08701, United States More Info
Site Public Contact
Contact
732-923-6564
[email protected]
Mridula A. George
Principal Investigator
Monmouth Medical Center
Long Branch New Jersey, 07740, United States More Info
Site Public Contact
Contact
732-923-6564
[email protected]
Mridula A. George
Principal Investigator
Rutgers Cancer Institute of New Jersey
New Brunswick New Jersey, 08903, United States More Info
Site Public Contact
Contact
732-235-7356
Mridula A. George
Principal Investigator
Robert Wood Johnson University Hospital Somerset
Somerville New Jersey, 08876, United States More Info
Site Public Contact
Contact
908-685-2481
[email protected]
Mridula A. George
Principal Investigator
Community Medical Center
Toms River New Jersey, 08755, United States More Info
Site Public Contact
Contact
732-557-8294
[email protected]
Mridula A. George
Principal Investigator
Glens Falls Hospital
Glens Falls New York, 12801, United States More Info
Site Public Contact
Contact
518-926-6700
Darci A. Gaiotti-Grubbs
Principal Investigator
NYU Winthrop Hospital
Mineola New York, 11501, United States More Info
Site Public Contact
Contact
212-263-4432
[email protected]
Douglas Marks
Principal Investigator
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York New York, 10016, United States More Info
Site Public Contact
Contact
[email protected]
Douglas Marks
Principal Investigator
Rex Hematology Oncology Associates-Cary
Cary North Carolina, 27518, United States More Info
Site Public Contact
Contact
919-784-2500
[email protected]
Anureet Copeland
Principal Investigator
Rex Hematology Oncology Associates-Garner
Garner North Carolina, 27529, United States More Info
Site Public Contact
Contact
919-784-2500
[email protected]
Anureet Copeland
Principal Investigator
UNC Rex Healthcare
Raleigh North Carolina, 27607, United States More Info
Site Public Contact
Contact
919-784-2500
[email protected]
Anureet Copeland
Principal Investigator
UNC Rex Cancer Center of Wakefield
Raleigh North Carolina, 27614, United States More Info
Site Public Contact
Contact
919-784-2500
[email protected]
Anureet Copeland
Principal Investigator
Miami Valley Hospital South
Centerville Ohio, 45459, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Jhansi L. Koduri
Principal Investigator
MetroHealth Medical Center
Cleveland Ohio, 44109, United States More Info
Site Public Contact
Contact
216-778-7559
[email protected]
Rakhshanda Layeequr Rahman
Principal Investigator
Dayton Blood and Cancer Center
Dayton Ohio, 45409, United States More Info
Site Public Contact
Contact
937-276-8320
Jhansi L. Koduri
Principal Investigator
Miami Valley Hospital
Dayton Ohio, 45409, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Jhansi L. Koduri
Principal Investigator
Miami Valley Hospital North
Dayton Ohio, 45415, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Jhansi L. Koduri
Principal Investigator
Atrium Medical Center-Middletown Regional Hospital
Franklin Ohio, 45005, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Jhansi L. Koduri
Principal Investigator
Miami Valley Cancer Care and Infusion
Greenville Ohio, 45331, United States More Info
Site Public Contact
Contact
937-569-7515
Jhansi L. Koduri
Principal Investigator
ProMedica Flower Hospital
Sylvania Ohio, 43560, United States More Info
Site Public Contact
Contact
419-824-1842
[email protected]
Feng Jiang
Principal Investigator
Upper Valley Medical Center
Troy Ohio, 45373, United States More Info
Site Public Contact
Contact
937-528-2900
[email protected]
Jhansi L. Koduri
Principal Investigator
University of Oklahoma Health Sciences Center
Oklahoma City Oklahoma, 73104, United States More Info
Site Public Contact
Contact
405-271-8777
[email protected]
Wajeeha Razaq
Principal Investigator
Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa Oklahoma, 74146, United States More Info
Site Public Contact
Contact
918-505-3200
Wajeeha Razaq
Principal Investigator
Legacy Mount Hood Medical Center
Gresham Oregon, 97030, United States More Info
Site Public Contact
Contact
503-413-2150
Mei Dong
Principal Investigator
Providence Newberg Medical Center
Newberg Oregon, 97132, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Charles W. Drescher
Principal Investigator
Saint Alphonsus Medical Center-Ontario
Ontario Oregon, 97914, United States More Info
Site Public Contact
Contact
406-969-6060
[email protected]
John M. Schallenkamp
Principal Investigator
Providence Willamette Falls Medical Center
Oregon City Oregon, 97045, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Charles W. Drescher
Principal Investigator
Legacy Good Samaritan Hospital and Medical Center
Portland Oregon, 97210, United States More Info
Site Public Contact
Contact
800-220-4937
[email protected]
Mei Dong
Principal Investigator
Providence Portland Medical Center
Portland Oregon, 97213, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Charles W. Drescher
Principal Investigator
Providence Saint Vincent Medical Center
Portland Oregon, 97225, United States More Info
Site Public Contact
Contact
503-215-2614
[email protected]
Charles W. Drescher
Principal Investigator
SWOG
Portland Oregon, 97239, United States More Info
Erin F. Cobain
Contact
[email protected]
Erin F. Cobain
Principal Investigator
Legacy Meridian Park Hospital
Tualatin Oregon, 97062, United States More Info
Site Public Contact
Contact
503-413-1742
Mei Dong
Principal Investigator
Smilow Cancer Hospital Care Center - Westerly
Westerly Rhode Island, 02891, United States More Info
Site Public Contact
Contact
203-785-5702
[email protected]
Mariya Rozenblit
Principal Investigator
Saint Joseph's/Candler - Bluffton Campus
Bluffton South Carolina, 29910, United States More Info
Site Public Contact
Contact
912-819-5704
[email protected]
Catherine A. Ronaghan
Principal Investigator
Tidelands Georgetown Memorial Hospital
Georgetown South Carolina, 29440, United States More Info
Site Public Contact
Contact
843-545-5600
[email protected]
Abirami Sivapiragasam
Principal Investigator
South Carolina Cancer Specialists PC
Hilton Head Island South Carolina, 29926, United States More Info
Site Public Contact
Contact
912-819-5704
[email protected]
Catherine A. Ronaghan
Principal Investigator
Baptist Memorial Hospital and Cancer Center-Collierville
Collierville Tennessee, 38017, United States More Info
Site Public Contact
Contact
901-226-1366
[email protected]
Ryan A. Yates
Principal Investigator
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis Tennessee, 38120, United States More Info
Site Public Contact
Contact
901-226-1366
[email protected]
Ryan A. Yates
Principal Investigator
University of Texas Health Science Center at San Antonio
San Antonio Texas, 78229, United States More Info
Site Public Contact
Contact
210-450-3800
[email protected]
Kate I. Lathrop
Principal Investigator
VCU Massey Cancer Center at Stony Point
Richmond Virginia, 23235, United States More Info
Site Public Contact
Contact
[email protected]
Masey M. Ross
Principal Investigator
Virginia Commonwealth University/Massey Cancer Center
Richmond Virginia, 23298, United States More Info
Site Public Contact
Contact
[email protected]
Masey M. Ross
Principal Investigator
Northwest Medical Specialties PLLC
Tacoma Washington, 98405, United States More Info
Site Public Contact
Contact
253-306-0532
[email protected]
Francis M. Senecal
Principal Investigator
Legacy Cancer Institute Medical Oncology and Day Treatment
Vancouver Washington, 98684, United States More Info
Site Public Contact
Contact
[email protected]
Mei Dong
Principal Investigator
Legacy Salmon Creek Hospital
Vancouver Washington, 98686, United States More Info
Site Public Contact
Contact
503-413-2150
Mei Dong
Principal Investigator
West Virginia University Charleston Division
Charleston West Virginia, 25304, United States More Info
Site Public Contact
Contact
304-388-9944
Ahmed A. Khalid
Principal Investigator
Saint Vincent Hospital Cancer Center Green Bay
Green Bay Wisconsin, 54301, United States More Info
Site Public Contact
Contact
920-433-8889
[email protected]
Matthew L. Ryan
Principal Investigator
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay Wisconsin, 54303, United States More Info
Site Public Contact
Contact
920-433-8889
[email protected]
Matthew L. Ryan
Principal Investigator
Saint Vincent Hospital Cancer Center at Oconto Falls
Oconto Falls Wisconsin, 54154, United States More Info
Site Public Contact
Contact
920-433-8889
[email protected]
Matthew L. Ryan
Principal Investigator
Saint Vincent Hospital Cancer Center at Sheboygan
Sheboygan Wisconsin, 53081, United States More Info
Site Public Contact
Contact
920-433-8889
[email protected]
Matthew L. Ryan
Principal Investigator
Saint Vincent Hospital Cancer Center at Sturgeon Bay
Sturgeon Bay Wisconsin, 54235, United States More Info
Site Public Contact
Contact
920-433-8889
[email protected]
Matthew L. Ryan
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 3

Estimated Enrollment:

3680

Study ID:

NCT06058377

Recruitment Status:

Recruiting

Sponsor:


National Cancer Institute (NCI)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.